Neko Health has secured $700 million in new funding as it prepares to expand its AI-powered preventive health screening services into the United States. The investment will support the company’s first U.S. clinic in New York while accelerating research, technology development, and future expansion into additional cities.
Founded by Spotify co-founder Daniel Ek and CEO Hjalmar Nilsonne, Neko Health is focused on making preventive healthcare more accessible through comprehensive body scans that combine artificial intelligence, advanced imaging, laboratory testing, and physician oversight.
A New Approach to Preventive Healthcare
Rather than replacing traditional medical care, Neko Health aims to provide a comprehensive health assessment during a single appointment.
The company’s screening process combines full-body imaging, blood tests, cardiovascular measurements, body composition analysis, skin mapping, and clinician consultations into one streamlined visit. Proprietary sensors capture thousands of high-resolution images while blood samples are analyzed on-site, allowing patients to review their results with a medical professional before leaving the clinic.
The goal is to identify potential health concerns such as cardiovascular disease, diabetes, and skin cancer before symptoms become more serious.
AI Supports, Doctors Decide
Artificial intelligence plays an important role throughout the screening process by helping collect, organize, and summarize large volumes of health information.
However, Neko emphasizes that clinicians remain responsible for reviewing findings, discussing results with patients, and recommending any necessary follow-up care. The company positions its technology as a decision-support tool rather than an autonomous diagnostic system.
Customers are also encouraged to continue working with their primary healthcare providers for diagnosis and treatment.
Expansion Into the United States
The newly announced funding will finance the launch of Neko’s first U.S. clinic in New York, with additional American locations planned in the future.
While the company has not revealed pricing for its U.S. services, its clinics currently operate in the United Kingdom and Sweden, where thousands of patients have already completed preventive health scans.
The expansion represents one of the largest international growth efforts for an AI-driven healthcare company focused on preventive medicine.
Building Proprietary Medical Technology
Unlike many digital health startups, Neko develops much of its own medical hardware.
Its latest generation of imaging devices is designed to collect more health data while automating larger portions of the scanning process. The company has also introduced new body composition measurements and expanded clinician reviews of wearable device data, giving physicians additional insights into a patient’s overall health.
By combining custom-built hardware with AI-powered software, Neko hopes to create a more efficient and comprehensive screening experience.
Regulatory Progress
As Neko prepares to enter the U.S. market, two of its internally developed medical devices recently received FDA clearance through the agency’s 510(k) pathway.
These approvals apply to specific medical devices rather than the company’s complete screening service, but they represent an important milestone as Neko expands its presence in the American healthcare market.
The company’s clinics will operate as preventive health providers, with patients being referred to outside specialists whenever additional diagnostic testing or treatment is needed.
Questions Still Remain
While Neko has attracted significant investor interest, questions remain about the long-term clinical impact of its approach.
Publicly available research has not yet demonstrated that the company’s complete screening model consistently improves patient outcomes compared with conventional preventive care. Ongoing studies are evaluating portions of the technology, but broader evidence regarding effectiveness, false-positive rates, and long-term health benefits is still developing.
Like many emerging healthcare technologies, wider adoption will likely depend on future clinical data as well as continued regulatory oversight.
Looking Ahead
Neko Health’s latest funding round reflects growing confidence that artificial intelligence can play a meaningful role in preventive medicine. By combining AI with advanced medical imaging, laboratory testing, and physician expertise, the company hopes to make early disease detection more accessible while encouraging people to take a proactive approach to their health.
As expansion into the United States begins, the company’s ability to demonstrate measurable clinical value will likely determine whether its AI-powered screening model becomes a mainstream part of preventive healthcare.
Source: https://www.artificialintelligence-news.com/news/neko-health-700m-ai-body-scans-us/
